Tagged with Novartis,

Turkey Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer to global organisations, why the well-educated and cost-efficient domestic labour force is so important to the Turkish pharma market’s future,…

Turkey Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over 95 percent of the population. The effort, part of the country’s Health Transformation Program introduced in 2003, has been commended by international organizations across the world. But today, as citizens…

Mexico During a year where the Mexican economy shrank 8.5 percent, Novartis Mexico experienced a modest one percent growth which Country President Fernando Cruz, qualified as “reasonably good” considering the impacts of COVID-19, down from 4.5 percent growth in 2019.   “In summary, our strategy for 2021 is to be aggressive…

Saudi Arabia As part of Saudi Arabia’s ambitious ‘Vision 2030’ economic transformation plan, the country has centralised the public procurement of medications through the National Unified Procurement Company for Medical Supplies (NUPCO). Here, some of the Kingdom’s most prominent pharma leaders weigh in on the impact of this new system for their…

Turkey Avinash Potnis of Novartis Turkey discusses potential solutions to the country’s access and pricing dilemma which has raised concerns of system sustainability. Potnis also highlights the strengths of Turkey’s healthcare infrastructure, workforce, and the country’s prospects as a globally competitive innovation hub.   Turkey has a unique value proposition, bringing…

Mexico The latest news from Mexican pharma, including Bayer’s big bet on oncology and Novartis’ aggressive expansion strategy as well as updates on the country’s vaccination drive, including the upcoming rollout of the J&J jab, why the country’s doctors are being denied vaccines, and the progression of trials for the Sanofi…

Saudi Arabia 33-year pharma industry veteran Georg Schroeckenfuchs currently heads up the vast Middle East & Africa (MEA) region for Swiss behemoth Novartis, overseeing 19 countries, over 1800 employees, and more than USD 900 million in revenues. In a recent conversation within the frame of PharmaBoardroom’s current focus on Saudi Arabia, the…

Saudi Arabia Georg Schroeckenfuchs, Novartis’ president MEA and head of its Gulf and Saudi Country Group, explains how the company’s objectives are aligned with Saudi Arabia’s Vision 2030, the progress made towards the nationalization of its Saudi workforce, the potential impact of changes in the tender process, and why Novartis is uniquely…

Switzerland The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based global behemoths, what value does Switzerland itself hold and what do they see as the areas in which they can truly bring value in their home market?   Roche – Driving Digital & Personalised…

Asia-Pacific Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a pressing need for more patient-centric, data-driven, value-based, and precise solutions in oncology. Additionally, Asian cancer patients’ healthcare needs can differ…

Global On World Intellectual Property (IP) Day 2021, the innovative biopharmaceutical industry came together to launch a new initiative foregrounding the benefits to patients and to society at large of a robust IP framework. Under the INTERPAT umbrella, 25 industry members and associations launched the ‘IP Principles for Advancing Cures and…

Switzerland Vincent Gruntz looks at the market dynamics for oncology in Switzerland, where an increasingly cost-conscious approach is being taken to reimbursement and pricing, his experience of bringing CAR-T therapies to the country, and the challenges and opportunities of ‘virtual’ product launches.   Once you have seen a patient – that…